复发转移性食管癌患者紫杉醇化疗联合50 Gy放疗的预后与安全性

Efficacy and safety of paclitaxel chemotherapy plus 50 gy radiotherapy for patients with recurrent and metastatic esophageal cancer

目的分析紫杉醇化疗联合50 Gy放疗治疗复发转移性食管癌的临床疗效和安全性。方法回顾性分析2015年1月至12月收治的83例复发转移性食管癌患者的临床资料,按照治疗方法的不同分为紫杉醇化疗联合50 Gy放疗组(治疗组,39例)和50 Gy放疗组(对照组,44例)。比较两组患者接受治疗后的近期疗效、不良反应发生率,3、6个月生存率。结果治疗组的总有效率明显高于对照组(79.5%vs 52.3%,P<0.05)。治疗组与对照组3个月的生存率分别为100%、95.5%,差异无统计学意义(P>0.05),6个月的生存率分别为100%、86.4%,差异有统计学意义(P<0.05)。两组恶心呕吐、食管炎、血小板减少、白细胞减少发生率比较差异无统计学意义(P均>0.05)。结论采用紫杉醇化疗联合50 Gy放疗方案治疗复发转移性食管癌有较好的临床疗效,患者耐受性好,不良反应发生率低,安全性高。

Objective To study the clinical effect and safety of paclitaxel chemotherapy combined with 50 gy radiotherapy in the treatment of recurrent and metastatic esophageal cancer. Methods A retrospective analysis was performed on the data of 83 patients with recurrent and metastatic esophageal cancer from January 2015 to December 2015. According to treatment method, the patients were divided into paclitaxel chematherapy plus 50 gy radiotherapy group （treatment group, n = 39） and 50 gy radiotherapy group （control group, n = 44）. The short term curative effects, the incidence of adverse re- action and the survival rates of 3-,6- month were analyzed and compared between two groups. Results The total effective rate of treatment group was significantly higher than that of control group （79.5% vs 52.3% , P 〈 0.05 ）. There was no sig- nificant difference in 3-month survival rate between treatment group and control group （ 100% vs 95.5% , P 〉 0.05 ） , but 6-monthin survival rate in treatment group was significantly higher than that in control group （ 100% vs 86.4% , P 〈 0. 05 ）. There were no significant differences in incidences of nausea and vomiting, esophagitis, thrombocytopenia and leuko- penia between two groups （ all P 〉 0.05）. Conclusions The combined treatment of paclitaxel chemotherapy and 50 gy ra- diotherapy has better clinical curative effect and the advantages of well tolerance of patients,lower incidence of adverse re- action and higher safety for the treatment of recurrent and metastatic esophageal cancer.